सभी अध्ययन
भर्तीचरण II और चरण III (एकीकृत)हस्तक्षेपात्मक

A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Myelodysplastic syndromes (MDS) are a group of conditions where the bone marrow struggles to make healthy red blood cells, often causing severe anaemia. Many people need regular blood transfusions to stay well, but standard medicines called ESAs do not always work or may stop working over time. This trial is looking at a medicine named imetelstat. Researchers want to find out whether imetelstat can help people with lower-risk MDS go without blood transfusions for at least 8 weeks in a row, and potentially longer. The study also tracks safety, side effects, overall health, and how well bone marrow functions over time. Half of the participants in the main phase receive the active drug, while others may receive a dummy treatment (placebo) to ensure fair comparison.

एक नजर में

स्थिति
भर्ती
चरण
चरण II और चरण III (एकीकृत)
प्रायोजक
Geron Corp.
नामांकन लक्ष्य
164
प्रारंभ
22 May 2024

यह अध्ययन किस बारे में है?

Myelodysplastic syndromes, or MDS, affect how your bone marrow produces blood cells. When the body cannot make enough healthy red blood cells, severe tiredness and breathlessness can occur. For many people with MDS, regular blood transfusions become an essential part of daily life to keep energy levels up. However, needing frequent transfusions can take a toll on quality of life and lead to other health complications.

While there are standard medicines designed to encourage the body to make more red blood cells, these treatments do not work for everyone, or they can lose their effect over time. When this happens, doctors have fewer options to offer. This clinical trial is testing a new treatment called imetelstat to see if it can help break this cycle.

Imetelstat works in a different way to standard treatments. Researchers want to know if it can help the bone marrow recover enough to produce its own red blood cells again. If successful, this could mean participants need far fewer transfusions, or even none at all for long periods, giving people more freedom and a better quality of life.

मुख्य निष्कर्ष

  • Tests a new medicine called imetelstat for adults with lower-risk MDS.
  • Aimed at people who depend on frequent red blood cell transfusions.
  • Designed for those whose anaemia has not improved with standard treatments.
  • A key goal is helping patients go at least 8 weeks without a transfusion.
  • भाग लेना स्वैच्छिक है, और आप किसी भी समय वापस ले सकते हैं।.

कौन पात्र हो सकता है?

This study is open to adults aged 18 and over who have been diagnosed with lower-risk or intermediate-risk myelodysplastic syndrome (MDS). To be considered, you must currently depend on regular red blood cell transfusions to manage your anaemia.

In addition, standard treatments—specifically medicines known as erythropoiesis-stimulating agents (or ESAs)—must have either stopped working for you or failed to help in the first place.

A doctor or study team will review your full medical history, blood results, and general organ health to ensure that taking part in the trial is safe and suitable for your specific situation.

क्या यह अध्ययन आपके लिए उपयुक्त हो सकता है?

यह देखने के लिए इन त्वरित प्रश्नों का उत्तर दें कि क्या आप पात्र हो सकते हैं। यह केवल एक मार्गदर्शिका है — अंतिम निर्णय शोध टीम द्वारा लिया जाता है।.

  1. I am aged 18 or older.
  2. I have been diagnosed with low or intermediate-risk MDS.
  3. I need regular red blood cell transfusions to manage my anaemia.
  4. Standard ESA treatments have either stopped working or did not work for me.
  5. I am able and willing to attend regular hospital appointments for treatment and tests.
अपने परिणाम देखने के लिए हर प्रश्न का उत्तर दें।.

भागीदारी में क्या शामिल है?

Taking part involves receiving either the study medicine (imetelstat) or an inactive dummy treatment (placebo) given through an intravenous drip into a vein. Because this is a controlled trial, neither you nor your doctor will know which treatment you are receiving at first, which ensures the results are completely unbiased.

You will have regular hospital visits for health checks. These include routine blood tests, checks on your vital signs (such as blood pressure and heart rate), heart tracings (ECGs), and monitoring how many blood transfusions you need. The study team will track your health closely to see if you can go at least 8 to 24 weeks without needing a transfusion. The study lasts for several months, followed by long-term check-ins to monitor your health and wellbeing.

संभावित जोखिम और लाभ

A potential benefit of joining this study is that imetelstat might reduce or stop your need for regular blood transfusions, which could boost your energy and daily independence. However, there is no guarantee you will directly benefit, and some participants may receive a placebo instead of the active medicine. Like all medicines, imetelstat can cause side effects, and your blood counts will need to be checked carefully. Your care team will monitor you closely and treat any problems quickly. Joining the trial is entirely voluntary, and you can change your mind and leave at any time without your regular NHS care being affected.

स्थान (8)

कुछ साइट स्थान अनुमानित हैं। हम इसे सुधार रहे हैं — कृपया यात्रा करने से पहले परीक्षण टीम से सत्यापित करें।.
  • —
    असत्यापित
    जर्मनी
  • —
    असत्यापित
    इटली
  • —
    असत्यापित
    चेकिया
  • —
    असत्यापित
    फ्रांस
  • —
    असत्यापित
    नीदरलैंड्स
  • —
    असत्यापित
    बेल्जियम
  • —
    असत्यापित
    स्पेन
  • —
    असत्यापित
    पोलैंड

सामान्य प्रश्न

What is imetelstat?

Imetelstat is an experimental medicine designed to treat certain bone marrow disorders by targeting abnormal cells and helping the body produce healthier blood cells.

What is the main goal of this trial?

The primary goal is to find out if imetelstat can help people go for at least 8 continuous weeks without needing a red blood cell transfusion.

Will I definitely receive the new medicine?

Not necessarily. In part of the trial, participants are randomly assigned by a computer to receive either imetelstat or a dummy drip (placebo) to ensure the study provides reliable results.

Can I still have blood transfusions if I need them?

Yes. Your safety and comfort come first. If your blood counts drop and you need a transfusion, your doctors will give you one immediately.

Can I leave the study early?

Yes. You have the right to withdraw from the trial at any point, for any reason, and your regular medical team will continue to look after you.

और अधिक जानने के लिए कैसे पता करें

किसी अध्ययन में भाग लेने का निर्णय लेने से पहले हमेशा अपने जीपी या विशेषज्ञ से बात करें।.

भाग लेने में रुचि रखते हैं?

अपनी रुचि दर्ज करें

अपने विवरण साझा करें और अनुसंधान टीम के लिए "A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Depe…यदि आप पात्र हो सकते हैं तो आपसे संपर्क करेंगे। भाग लेने के लिए सहमति देने से पहले हमेशा अपने जीपी से बात करें।.

चर्चा

समुदाय चर्चा

हमारे फोरम द्वारा संचालित community.patient.info. कृपया सम्मानजनक रहें — यह चिकित्सा सलाह नहीं है।.